

12-17-03



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/663,258
		Filing Date	September 16, 2003
		First Named Inventor	Jose Engelmayr
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	1	Attorney Docket Number	HO-P02652US1

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	16 References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		


## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	FULBRIGHT & JAWORSKI L.L.P. Melissa W. Acosta
Signature	
Date	December 16, 2003

### Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. er 147059868 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 16, 2003

Signature:  (Annette Devereux)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. er 147059868 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 16, 2003 Signature

(Annette Devereux)

Docket No.: HO-P02652US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Index Patent Application of:  
Joseph Engelmayr, et al.

Application No.: 10/663,258

Confirmation No.:

Filed: September 16, 2003

Art Unit: N/A

For: **LACTOFERRIN COMPOSITIONS AND  
METHODS OF WOUND TREATMENT**

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02652US1. A duplicate copy of this paper is enclosed.

Dated: December 16, 2003

Respectfully submitted,

By   
Melissa W. Acosta  
Registration No.: 45,872  
FULBRIGHT & JAWORSKI L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-5151  
(713) 651-5246 (Fax)



Handicapped Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/663,258
Sheet	1	of	2	Filing Date	September 16, 2003
				First Named Inventor	Jose Engelmayr
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02652US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA	US-5457093	10-10-1995	Cini et al.		
AB	US-6333311-B1	12-25-2001	Nuijens et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	WO-02100445-A1	12-19-2002	The University of Sydney		T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CA	Yang et al, "Antitumor Activity and Specificity as a Function of Substitutions in the Lipophilic Sector of Helical Lactoferrin-derived Peptide," <i>Journal of Peptide Science</i> 9, 2003, pp. 300-311.			
	CB	Takayama et al, "The Bovine Lactoferrin Region Responsible for Promoting the Collagen Gel Contractile activity of Human Fibroblasts," <i>Biochemical and Biophysical Research Communications</i> 299 (2002), pp 813-817.			
	CC	Yang et al., "Enhanced Antitumor Activity and Selectivity of Lactoferrin-derived peptides," <i>J. Peptide Res.</i> 60, 2002, pp. 187-197.			
	CD	Takayama et al, "Effects of Lactoferrin on Collagen Gel Contractile Activity and Myosin Light Chain Phosphorylation in Human Fibroblasts," <i>FEBS Letter</i> 508, 2001, pp. 111-116.			
	CE	Clarke et al, "Evaluation of Bovine Lactoferrin as a Topical Therapy for Chemotherapy-induced Mucositis in the Golden Syrian Hamster," <i>Oral Oncology</i> 35, 1999, pp. 197-202.			
	CF	Fujihara et al, "Lactoferrin Protects Against UV-B Irradiation-Induced Corneal Epithelial Damage in Rats," <i>Cornea</i> 19(2); 2000, pp. 207-211.			
	CG	Nakajima et al, "Lactoferrin as a Suppressor of Cell Migration of Gastrointestinal Cell Lines," <i>Journal of Cellular Physiology</i> 170, 1997, pp. 101-105.			
	CH	Weinberg, Eugene, "The Therapeutic Potential of Lactoferrin," <i>Expert Opinion Investig. Drugs</i> , 12(5), 2003, pp. 841-851.			
	CI	Cumberbatch et al, "IL-1 B-induced Langerhans' cell Migration and TNF-A production in Human Skin: Regulation by Lactoferrin," <i>Clin Exp. Immunol</i> 132, 2003, pp. 352-359.			
	CJ	He et al, "The Inhibition of Mast Cell Activation by Neutrophil Lactoferrin: Uptake by Mast Cells and Interaction with Tryptase, Chymase and Cathepsin G," <i>Biochemical Pharmacology</i> 65, 2003, pp. 1007-1015.			
	CK	Kimber et al, "Lactoferrin: Influence on Langerhans Cells, Epidermal Cytokines, and Cutaneous Inflammation," <i>Biochem Cell Biol.</i> 80, 2002, pp. 103-107.			
	CL	Ward et al, "Lactoferrin and Host Defense," <i>Biochem Cell Biol.</i> 80, 2002, pp. 95-102.			
	CM	Cumberbatch et al, "Regulation of Epidermal Langerhans Cell Migration by Lactoferrin," <i>Immunology</i> 2000, 100, pp. 21-28.			

Examiner Signature	Date Considered
--------------------	-----------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002.OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE  
Bend to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<p><b>Complete if Known</b></p>	
<p>Sheet</p>		<p>2</p>	<p>of</p>	<p>2</p>	<p>Attorney Docket Number</p>
					<p>10/663,258</p>
					<p>September 16, 2003</p>
					<p>Jose Engelmayer</p>
					<p>N/A</p>
					<p>Not Yet Assigned</p>

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/663,258

---

Attorney Docket No.: HO-P02652US1

DEC 16 2000

DEC 16 2003  
U.S. PATENT & TRADEMARK OFFICE

**Certificate of Express Mailing Under 37 CFR 1.10**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. er 147059868 US in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on December 16, 2003  
Date

Signature

**Annette Devereux**

**Note:** Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

### IDS (Citation) by Applicant